Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 10/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208916 | 1.00 | MAP4K1 (0.38) | MAP4K1CYP11B1CYP11B2HSD17B13NTRK1 | |
| SCHEMBL1324469 | 0.89 | ALDH1A1 (0.47) | KMT2AKDM4EMEN1ALDH1A1NPSR1 | |
| SCHEMBL1324471 | 0.89 | ALDH1A1 (0.47) | KMT2AKDM4EMEN1ALDH1A1NPSR1 | |
| SCHEMBL3825827 | 0.83 | NTRK1 (0.38) | NTRK1THRBRXFP1 | |
| SCHEMBL2211274 | 0.82 | ELANE (0.42) | NTRK1ALDH1A1 | |
| SCHEMBL2211280 | 0.82 | ELANE (0.42) | NTRK1ALDH1A1 | |
| SCHEMBL3611030 | 0.82 | CNR2 (0.35) | NTRK1XIAPTHRBRXFP1 | |
| SCHEMBL2209975 | 0.82 | NTRK1 (0.37) | NTRK1KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2209965 | 0.82 | NTRK1 (0.37) | NTRK1KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL1323051 | 0.82 | CNR2 (0.35) | NTRK1XIAPTHRBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| CN-101535273-A | 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases | NOVARTIS AG (CH) | 2009-09-16 | — | — | CN | claimed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | MAP4K1 3283/4885CYP11B1 796/4885CYP11B2 1159/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | MAP4K1 3283/4885CYP11B1 796/4885CYP11B2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.